Study Title: SPECTRE

Study Description: Combined Suppression Of Cholesterol Bioavailability And Androgen Deprivation Therapy To Treat Castration Resistant Prostate Cancer

Study Design: Single-arm phase II trial

Trial Status: open to recruitment

Chief Investigator: Prof Hing Leung, Beatson West of Scotland Cancer Centre, Glasgow

Sponsor: University of Glasgow/NHS Greater Glasgow & Clyde

Date Opened: 20th December 2016

Planned Closure Date: December 2018

Target Recruitment: 40 patients

Open to New Sites: Not Applicable, single-centre only

Contact Details:

Clinical Trials Unit, Glasgow (CTUG)

Project Manager:
Laura Alexander [email protected]
Tel: 00 44 (0) 141 301 7212
Fax: 00 44 (0) 141 301 7244

Clinical Trial Co-ordinator:
Avril Trevethan [email protected]
Tel: 00 44 (0) 141 301 7467
Fax: 00 44 (0) 141 301 7228

Cancer Research UK Clinical Trials Unit,
Beatson West of Scotland Cancer Centre,
1053 Great Western Road,
Glasgow, G12 0YN

Click here to download the Initiation Slides

Pharmacovigilance Documentation

Clinical Management Reference Documents

These are the current Summary of Product Characteristics (SmPCs) to be referred to for the clinical management of trial patients:

For queries concerning Pharmacovigilance or the documents acting as the Reference Safety Information please contact:

The Pharmacovigilance Team email: [email protected] or
Telephone: 0141 211 0352/0203/3567/3968 or 0141 232 2068

Version of NCI Common Terminology Criteria for Adverse Events (CTCAE) being used for the study (if applicable): 4.03

Click here to download the CTCAE